Public Health Agency of Canada / Agence de santé publique du Canada
Skip all navigation -accesskey z Skip to sidemenu -accesskey x Skip to main menu -accesskey m Skip all navigation -accesskey z
Français Contact Us Help Search Canada Site
PHAC Home Centres Publications Guidelines A-Z Index
Child Health Adult Health Seniors Health Surveillance Health Canada

Volume 22, No. 1 - 2001 

 

 

Public Health Agency of Canada (PHAC)

Emigration Patterns of Cancer Cases in Alberta, Canada

Juanita Hatcher and Marilou Hervas


Volume 22, No. 1 - 2001  

Abstract

Cancer registries are a unique source of data for population-based analysis of survival of cancer cases, but information on current vital status is essential. This paper describes a method to determine the last known vital status of cases and the emigration pattern of cancer cases diagnosed in Alberta. Data from the Alberta Cancer Registry (ACR) for the years 1985-1993 (83,446 cases) were linked to the Alberta Health Care Insurance Plan (AHCIP) registration file to identify cases that had left the province and the date they emigrated. Ninety-nine percent of the ACR cases linked correctly to the AHCIP registration file. Three percent of cases had left Alberta by March 1998. For the first five years of follow-up between 0.6% and 0.8% of cases alive at the beginning of each year of follow-up left the province in the succeeding year. Seven percent of those diagnosed under 45 years of age left the province compared to less than 2% of those aged 65 and over. There was no difference in emigration patterns between the sexes. The cancer sites with good prognosis tended to have the highest proportion of emigrants.

Key words: cancer; emigration


Introduction

The primary function of cancer registries is to identify and register all incident cancer cases occurring within their jurisdiction and to record information related to the death of each cancer case.1 Cancer registries are thus a unique source of data for analyzing the survival of the population of cancer cases.2 As many cancer registries do not actively follow up the incident cases, however, the residency and current vital status of those not known to be dead are often unknown, as is the impact of emigration on survival.

In Alberta, Canada, the problems caused by lack of active follow-up were overcome by linking the Alberta Cancer Registry (ACR) to the Alberta Health Care Insurance Plan (AHCIP) registration file maintained by Alberta Health and Wellness (AHW). This enabled the ACR to identify those cancer cases that had left the province and the date that they left. This date would be used as a censoring date in survival analysis, permitting the determination of the extent of emigration of cancer cases from Alberta and the potential impact on survival analysis.

This paper describes the pattern of emigration of cancer cases diagnosed in Alberta.


Data

AHW maintains a historical database of all residents of the province of Alberta who are/were registered in AHCIP, which insures all required medical care available in the provinces. The contract holder pays the premiums, and benefits are provided for all members of the immediate family. All residents of Alberta, except serving members of the Royal Canadian Mounted Police and the Canadian Military, inmates of federal penitentiaries and Status Indians, are eligible to register in AHCIP. The federal government pays the AHCIP premiums for Status Indians and other exceptions who are included in the AHCIP registration file. Only 200-300 of the approximately 3 million who are eligible to register choose not to. The AHCIP registration file includes data on more than 99% of the Alberta population.

The AHCIP registration data include a unique personal identifier, the Personal Health Number (PHN) and/or the AHCIP number, surname, initials, date of birth, gender and postal code, as well as the date and reason for any changes in coverage by AHCIP. Prior to 1994, the individual identifier (AHCIP number) consisted of an eight-digit base number to identify the contract, and a three-digit individual identifier. If a person changed the contract under which he or she was covered, by, for example, leaving the family home to marry, his or her AHCIP number would change. The PHN, introduced in 1994, is unique to an individual and remains the same for life. AHW has assigned a PHN to people who were initially registered before 1994, and a conversion file exists to link pre-1994 AHCIP numbers to the new PHNs. AHW is usually informed of people who leave the province by the medical plan of the province to which the person has emigrated. The AHCIP file is linked to the vital statistics file on a weekly basis to identify those who have died in the province. The estate of a dead person may also notify AHW when it receives the bill for the premiums.

The ACR is mandated under the Alberta Cancer Program Act to capture information on every incident of invasive cancer diagnosed in Alberta.3 Pathology reports and death information from the Alberta Registries vital statistics file are the two main sources for identifying incident cases of cancer in Alberta. The ACR includes identifying information, (PHN, AHCIP number, current surname, previous surnames, first names, date of birth, gender and postal code); information on the incident tumour; and for those cases known to have died, date and cause of death. The Alberta Registries vital statistics file also provides information on cases that have died in Alberta. The ACR would not generally be informed of the deaths in other provinces. There has been no follow-up information on cases that are not known to have died.


Methods

All invasive cancer cases diagnosed in Alberta between January 1, 1985, and December 31, 1993, inclusive were identified from the ACR. A file containing PHN, AHCIP number, surname, initials, gender and date of birth for each individual diagnosed with cancer was submitted to AHW. This file included records for residents and non-residents of Alberta. A hierarchical deterministic linkage strategy was used to link the ACR to the AHCIP registration file, linking on the AHCIP number, the AHCIP base number and surname, gender and month and year of birth (identical). All links were checked using the other identifying information common to the two files.

Discrepancies between the ACR and the AHCIP records were investigated further by reviewing the patient's chart. Errors in the ACR were corrected, and AHW was notified of suspected errors in its data set. The agreement in the vital statistics of the linked cancer cases in the two files was also checked. Where the ACR had recorded that a case had died, but the AHCIP record indicated the case was alive, the death information held by the ACR was confirmed. In cases where AHCIP indicated the case had died but the ACR had no record of death, the case was deemed to be dead for subsequent analysis and the death date taken as that recorded by AHCIP. The ACR also had death information on some cases that AHCIP deemed had left the province.

Cases for which the first invasive primary (excluding non-melanoma skin cancer) occurred between 1985 and 1993 and which were resident in Alberta at the time of diagnosis were identified from the linked cohort. The percentage of cases that had left the province as determined from AHCIP was examined for each cancer site. Crude, age specific and age-standardized percentages were estimated. The standard population used was the total population of cancer cases used in the analysis. The percentage emigrating each year up to five years past diagnosis was estimated using the revised ACR vital status definitions. Person-years at risk were calculated as the time between diagnosis and date of last follow-up, death, emigration or for those still alive and resident in Alberta, as of March 31, 1998. All follow-up periods were terminated at five years to standardize the potential length of follow-up. The reduction in person-years at risk produced by censoring emigrants at the time of emigration rather than as of March 31, 1998, was investigated.


Results

Of the 83,446 cases that were resident in Alberta for at least one diagnosis between 1985 and 1993, 82,466 cases (98.8%) linked correctly to the AHCIP registration file. There was no difference in linkage rate between those who were registered as dead (98.8%) and those who were not registered as dead (98.8%).

The following results are presented for the 82,466 cases who were residents in Alberta at the time of diagnosis between 1985 to 1993, and who linked successfully with the AHCIP registration file (Table 1). Of the 45,925 cases that were registered as dead on the ACR, 97.3% were also registered as dead on the AHCIP registration file, 1.8% were registered as still alive and 0.9% were registered as having left the province. Of the 36,541 cases that were not registered as dead on the ACR, 1.3% were registered as dead on the AHCIP registration file and 5.6% had left the province. Of the 44,689 cases who were confirmed as dead on both the ACR and the AHCIP registration file, 574 (1.3%) of the dates of death do not agree between the two files. In 95% of these cases the AHCIP registration death date is later than that of the ACR. The discrepancies can be quite large: only 31% have differences of less than one year.

The following results are presented for the 76,164 cases of a first primary invasive cancer (excluding non-melanoma skin cancer) diagnosed between 1985 and 1993 while resident in Alberta. On average, 3.0% of the cases had left Alberta by 1998. (Table 2) This is somewhat lower than the age-standardized five-year emigration rate from Alberta between 1991 and 1996 of 3.5%.4 For the cohort of cases diagnosed between 1985 and 1993, and followed until March 1998, the cancer sites with the highest proportion of emigrants were testicular cancer (9.0%), cervical cancer (6.5%) and melanoma skin cancer (6.3%). The cancer sites with the lowest proportion of emigrants were prostate cancer (1.9%), lung cancer (1.6%) and pancreatic cancer (0.9%) (Table 2). Age standardization removes these differences except for those cancers with short survival rates, lung and pancreatic cancer, and for prostate cancer. In general, younger cancer cases were more likely to emigrate than older ones, but there is little difference in emigration rates among cancer sites. (Table 3).

For the first five years of follow-up, between 0.6% and 0.8% of all cases alive at the beginning of each year of follow-up left the province during the succeeding year (Table 4). This pattern continues after five years of follow-up. There are no marked differences in the patterns of emigration among the cancer sites. There are no differences in emigration patterns between the sexes.

The person-years at risk for the first five years of follow-up is reduced on overall by 1.7% of the total person-years at risk if all persons not known to be dead are assumed to be alive. The largest effect (3.5% reduction) is seen for cancer of the testis, and the smallest (0.8% reduction) for cancer of the prostate.




TABLE 1
Agreement between linked records for vital status on ACR and AHCIP files

ACR vital status

AH vital status

Dead

Alive

Left Alberta

Total

Dead

44,689

  (97.3%)

   836

   (1.8%)

  400

  (0.9%)

45,925

  (55.7%)

Alive

   478

   (1.3%)

34,012

  (93.1%)

2,051

  (5.6%)

36,541

  (44.3%)

Total

45,167

  (54.8%)

34,848

  (42.3%)

2,451

  (3.0%)

82,466

 



TABLE 2
Vital status of cancer cases diagnosed by cancer site in Alberta 1985-1993 as determined from 1998 AHCIP files

 

Dead

(%)

[adja %]

Alive in AB

(%)

[adja%]

Left AB

(%)

[adja %]

Total

Prostate

 4,322

46.4

40.5

 4,816

51.7

57.6

  177

1.9

1.9

 9,315

Female breast

 3,383

31.3

34.1

 7,007

64.8

62.4

  418

3.9

3.5

10,808

Lung

 8,634

87.9

85.7

 1,029

10.5

12.4

  161

1.6

1.9

 9,824

Colorectal

 4,999

57.0

53.9

 3,531

40.3

42.9

  235

2.7

3.2

 8,765

Melanoma skin

   428

19.1

29.7

 1,668

74.5

66.2

  142

6.3

4.1

 2,238

NHLb

 1,374

55.0

57.6

 1,039

41.6

39.3

   87

3.5

3.1

 2,500

Leukemia

 1,392

58.5

61.3

  911

38.3

35.9

   78

3.3

2.8

 2,381

Uterus

   528

23.7

26.3

 1,627

73.1

70.4

   72

3.2

3.3

 2,227

Bladder

 1,191

44.6

40.3

 1,368

51.3

54.8

  109

4.1

4.9

 2,668

Kidney

   940

48.1

50.4

  929

47.5

45.4

   86

4.4

4.1

 1,955

Testis

    34

 5.1

40.8

  571

85.9

56.0

   60

9.0

3.2

   665

Cervix uteri

   394

31.6

48.2

  771

61.9

48.0

   81

6.5

3.7

 1,246

Pancreas

 1,968

95.3

92.9

   79

 3.8

 6.2

   19

0.9

1.0

 2,066

Other

11,161

63.8

67.0

 5,812

33.2

30.4

  533

3.0

2.7

17,506

Total

40,748

54.9

 

31,158

42.0

 

2,258

3.0

 

74,164

a Age adjusted to the total cohort age distribution
b Non-Hodgkin's Lymphoma


TABLE 3
Distribution by age and site of cancer cases who left Alberta after diagnosis 1985-1993

Age

0-44 yrs

45-64 yrs

65-74 yrs

 

Site

Left/
Diagnosed

%

Left/
Diagnosed

%

Left/
Diagnosed

%

 

Prostate

0/10
0.0
60/1,924
3.1
69/3,892
1.8
 

Female breast

105/1,892
5.5
212/4,751
4.5
58/2,355
2.5
 

Lung

12/317
3.8
83/3,670
2.3
35/3,470
1.0
 

Colorectal

29/404
7.2
108/2,871
3.8
49/2,593
1.9
 

Melanoma skin

88/928
9.5
47/776
6.1
4/303
1.3
 

NHLa

40/493
8.0
25/910
2.7
13/578
2.2
 

Leukemia

40/640
6.3
16/654
2.4
12/524
2.3
 

Uterus

8/155
5.2
39/1,005
3.9
13/675
1.9
 

Bladder

23/172
13.4
52/876
5.9
22/832
2.6
 

Kidney

22/265
8.3
45/795
5.7
13/520
2.5
 

Testis

56/584
9.6
4/73
5.5
0/7
0.0
 

Cervix uteri

58/659
8.8
20/350
5.7
2/143
1.4
 

Pancreas

1/66
1.5
3/614
0.5
7/646
1.1
 

Other

262/3,564
7.4
169/5,761
2.9
66/4,174
1.6
 

Total

744/10,149
7.3
883/25,030
3.5
363/20,712
1.8
 

a Non-Hodgkin's Lymphoma


TABLE 3 (cont'd)
Distribution by age and site of cancer cases who left Alberta after diagnosis 1985-1993

Age

75-84 yrs

85+ yrs

Total

Site

Left/
Diagnosed

%

Left/
Diagnosed

%

Left/
Diagnosed

Prostate

38/2,772
1.4
10/717
1.4

177/9,315

Female breast

32/1,379
2.3
11/431
2.6

418/10,808

Lung

27/2,000
1.4
4/367
1.1

161/9,824

Colorectal

33/2,129
1.6
16/768
2.1

235/8,765

Melanoma skin

3/166
1.8
0/65
0.0

142/2,238

NHLa

8/413
1.9
1/106
0.9

87/2,500

Leukemia

9/399

2.3

1/164
0.6

78/2,381

Uterus

11/332
3.3
1/60
1.7

72/2,227

Bladder

10/611
1.6
2/177
1.1

109/2,668

Kidney

6/294
2.0
0/81
0.0

86/1,955

Testis

0/1
0.0
0/0
 

60/665

Cervix uteri

0/67
0.0
1/27
3.7

81/1,246

Pancreas

7/511
1.4
1/229
0.4

19/2,066

Other

25/2,940
0.9
11/1,067
1.0

533/17,506

Total

209/14,014
1.5
59/4,259
1.4

2,258/74,164

a Non-Hodgkin's Lymphoma


TABLE 4
Distribution of time from diagnosis to leaving Alberta, by cancer site, for cancer cases diagnosed in Alberta 1985-1993

Interval

0-<1 yr

1-<2 yrs

2-<3 yrs

#
alive
at
begin-
ning
of interval

#
leav
-ing
in
interval

%
leav-
ing
in
interval

#
alive
at
begin-
ning
of interval

#
leav
-ing
in
interval

%
leav-
ing
in
interval

#
alive
at
begin-
ning
of interval

#
leav
-ing
in
interval

%
leav-
ing
in
interval

Site

Prostate

 9,309

 31

0.3

 8,302

 28

0.3

 7,402

 30

0.4

Female breast

10,801

 51

0.5

10,161

 73

0.7

 9,415

 66

0.7

Lung

 9,821

 71

0.7

 3,367

 28

0.8

 1,929

 22

1.1

Colorectal

 8,763

 45

0.5

 6,477

 51

0.8

 5,385

 42

0.8

Melanoma
skin

 2,235

 19

0.9

 2,138

 29

1.4

 2,022

 31

1.5

NHLa

 2,498

 19

0.8

 1,788

 17

1.0

 1,518

 18

1.2

Leukemia

 2,380

 18

0.8

 1,637

 16

1.0

 1,395

 15

1.1

Uterus

 2,227

 12

0.5

 2,050

 18

0.9

 1,932

  9

0.5

Bladder

 2,667

 16

0.6

 2,252

 21

0.9

 1,994

 19

1.0

Kidney

 1,954

 17

0.9

 1,401

 13

0.9

 1,247

 15

1.2

Testis

   665

  9

1.4

   640

 14

2.2

   615

  5

0.8

Cervix
uteri

 1,244

 14

1.1

 1,089

 11

1.0

   951

 16

1.7

Pancreas

 2,066

 17

0.8

   294

  2

0.7

   123

  0

0.0

Other

17,499

142

0.8

10,221

102

1.0

 8,187

 83

1.0

Total

74,129

481

0.6

51,817

423

0.8

44,115

371

0.8

a Non-Hodgkins Lymphoma




TABLE 4 (cont'd)
Distribution of time from diagnosis to leaving Alberta, by cancer site, for cancer cases diagnosed in Alberta 1985-1993

Interval

3-<4 yrs

4-<5 yrs

#
alive
at
begin-
ning
of interval

#
leav
-ing
in
interval

%
leav-
ing
in
interval

#
alive
at
begin-
ning
of interval

#
leav
-ing
in
interval

%
leav-
ing
in
interval

Site

Prostate

 6,014

 26

0.4

 4,731

 17

0.4

Female breast

 8,084

 52

0.6

 6,702

 37

0.6

Lung

 1,315

  9

0.7

   960

 13

1.4

Colorectal

 4,292

 28

0.7

 3,412

 13

0.4

Melanoma
skin

 1,741

 16

0.9

 1,441

 13

0.9

NHLa

 1,232

  6

0.5

   999

  8

0.8

Leukemia

 1,152

  8

0.7

   935

  7

0.7

Uterus

 1,704

  5

0.3

 1,480

  7

0.5

Bladder

 1,763

 11

0.6

 1,567

  9

0.6

Kidney

 1,047

 10

1.0

   862

 13

1.5

Testis

   568

  7

1.2

   501

  3

0.6

Cervix
uteri

   821

 10

1.2

   707

  9

1.3

Pancreas

    77

  0

0.0

    52

  0

0.0

Other

 6,728

 46

0.7

 5,515

 47

0.9

Total

36,538

234

0.6

29,864

196

0.7

a Non-Hodgkins Lymphoma


TABLE 5
Person-years of follow-up with and without censoring at time of emigration for cancer cases diagnosed in Alberta, 1985-1993

Site

Total person-years of follow-up

Difference

%

Not censored

Censored

Prostate

 33,099

 32,829

  270

0.82

Female breast

 43,165

 42,542

  623

1.46

Lung

 11,852

 11,673

  179

1.54

Colorectal

 25,332

 24,988

  344

1.38

Melanoma skin

  9,339

  9,078

  262

2.88

NHL

  7,248

  7,079

  169

2.38

Leukemia

  6,630

  6,523

  108

1.65

Uterus

  9,026

  8,898

  129

1.45

Bladder

  9,726

  9,550

  176

1.84

Kidney

  5,945

  5,801

  144

2.48

Testis

  2,982

  2,883

  100

3.47

Cervix uteri

  4,639

  4,497

  142

3.15

Pancreas

  1,218

  1,198

   20

1.65

Other

 41,137

 40,218

  919

2.28

Total

211,338

207,755

3,583

1.72



   

Discussion

Survival analysis requires the follow-up of all incident cancer cases included in the analysis so that their current vital status is known. The ability of cancer registries to follow up cases is dependent on the health care system in which the registry operates, and the registration practice of each registry.5 The main method of determining the death information for each cancer case is to link to the death certificate data for the jurisdiction of the registry. The ability to determine whether a case has left the jurisdiction of the registry and thus is lost to follow-up varies among registries. For the Scandinavian registries, complete follow-up is possible due to the existence of a unique lifetime identifier for each citizen. Thus date of emigration and date of death are known for all cancer cases.5 In Saarland, Germany, follow-up is largely passive, due to restrictive legislation. It is possible to determine the death information for cases that die in Saarland, but not whether a case has emigrated.5 In Canada, each of the provinces and territories operates its own registry and submits data to the national Canadian Cancer Registry. Most of these registries link their data to provincial vital statistics death information to determine the death information for those cases that die within the relevant province or territory. The Canadian Cancer Registry is linked to the National Death file for determining deaths among all cases that occurred anywhere in Canada. At the time of this study, the national death linkages have not been completed for the more recent years.

To overcome this problem, the ACR sought other solutions to determine the current residence and vital status of those cancer cases not known to have died. The AHCIP registration file, which AHW maintains, provided ACR with the required information. Deterministic linkages were used in preference to probabilistic linkages because of the availability of the AHCIP number. Evaluation of the linkage confirmed that it provided a high degree of accuracy (98.8% among cases resident in Alberta). However, this information is subject to the problems inherent in using administrative data in an application for which such data were not originally planned.6 Some of these problems have been identified, but not resolved, in this study. There are small percentages of cases in which the vital status is different in the two files (1.6%), in which the recorded residency patterns do not seem to concur with the stated residency in the ACR (1.6%), and in which the death dates do not agree (1.7%). The discrepancy in vital status could be explained by the potential delay in registering deaths on the AHCIP registration file for those cases that are dead in the ACR data and alive in the AHCIP data. For those cases that are alive in the ACR data and dead in the AHCIP data, the absence of the PHN on the ACR record may have prevented appropriate linkage to the Alberta Registries vital statistics death data, or these may be Alberta residents who died outside the province. These cases would not be included in the Alberta Registries vital statistics computer files. However, AHW may have been notified of the death when payment to AHCIP ceased.

The main aim of the project was to identify the residency and vital status of those cases that were not identified as dead so that cases leaving the province could be censored at the date of leaving in any survival analysis. The linkage has shown that cancer cases do in fact move out of the province, although they are less likely to migrate than the general population.4 The probability of their emigration depends on the site of their cancer, their age, and the time since diagnosis. As would be expected, those who are diagnosed at a younger age, and are diagnosed with a site for which there is a good prognosis, are more likely to move out of the province. The low emigration rate (1.9 %) for prostate cancer, which has a relatively good prognosis, may in part be explained by the advanced age at diagnosis. Both the good prognosis and the younger age at diagnosis can explain the high emigration rates for cancer of the testis, cervix and melanoma. Among those cases that migrate, the proportion of live cases that migrate on an annual basis does not vary appreciably among the cancer sites.

The implications of these findings on the results of survival analysis may be sizeable depending on the reasons that the cases migrate. If the cases that migrate were the ones for whom the prognosis is good compared to others with the same diagnosis, the survival rates would tend to be underestimated. However, if the ones who leave have poor prognoses compared to others with the same diagnosis then the survival rates would be overestimated. The cause-specific survival of foreign residents of Geneva diagnosed with cancer is superior than that of native residents, which may be due to a combination of the healthy immigrant bias and/or the repatriation of those cases with poor prognosis (unhealthy emigrant bias).7 The Alberta data show that the proportion of cases migrating from Alberta tends to be related to the overall prognosis of the diagnosis. The ACR has not collected staging information, and therefore is not able to address the issue of the prognosis of those cases who emigrate relative to those who remain in Alberta. However, the similarity of the distribution of time to emigration among the cancer sites for those who migrate would not indicate any systematic emigration patterns within site, based on prognosis.

Censoring of the emigrants at the time they leave the province decreases the overall person-years at risk by 1.7%. Although this figure is small, it may have a marked effect on survival estimates, particularly where survival is short or emigration is high. In the Eurocare II study, active follow up of lung cancer cases not known to be dead after five years resulted in decreases in five-year survival of up to 2.5%.5

Alberta is able to identify the cases who emigrate because the AHCIP registration file is updated regularly, in part to ensure that appropriate health care premiums are paid. In other provinces, the health care registration file may either not be available to the cancer registry or may not be sufficiently up to date. Thus the national death clearance which is currently being undertaken is essential for provincial cancer registries to improve their survival analysis. However, this death clearance will not identify cases who die outside of Canada and thus linkage with the AHCIP registration may still be of value.

The economy in Alberta is largely dependent on the oil and natural gas industry, which fluctuates with world economic conditions. The economy tends to drive the emigration pattern for the younger age group, while that of the older age groups may be driven by the desire to seek more clement winter conditions in other provinces or jurisdictions. Given these patterns of emigration, the results may not be applicable to other jurisdictions, but do indicate that emigration of cancer cases is an issue that should be addressed when undertaking survival analysis.


References

1.    Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG. Cancer Registration: Principles and Methods. Lyon: International Agency for Research on Cancer, 1991; IARC Scientific Publications No 95.

2.    Parkin DM, Wagner G, Muir, CS. The Role of the Registry in Cancer Control. Lyon: International Agency for Research on Cancer, 1985; IARC Scientific Publications No 66.

3.    Government of Alberta. The Alberta Cancer Programs Act (1992). Chapter C-1, Part 1.1.

4.    Statistics Canada. Interprovincial migrants 5 years and over (place of residence 5 years ago) by age group, sex and mother tongue, showing province or territory of residence 5 years ago for Canada, Provinces and Territories 1991 and 1996 Censuses (20% sample data). Ottawa, 1998; Cat. 93F0028XDB96010.

5.    Berrino F, Sant M, Verdecchia A, Capocaccia R, Hakulinen T, Esteve J. Survival of Cancer Patients in Europe: The EUROCARE Study. Lyon: International Agency for Research on Cancer, 1995; IARC Scientific Publications No 132.

6.    Tennis P, Andrews E, Bombardier C, Wang Y, Strand L, West R, et al. Record linkage to conduct an epidemiologic study on the association of rheumatoid arthritis and lymphoma in the province of Saskatchewan, Canada. J Clin Epid 1993;46:685-95.

7.    Raymond L, Fischer B, Fioretta G, Bouchardy C. Emigration bias in cancer survival rates. J Epi & Biostat 1996;3:167-173.


Author References

Juanita Hatcher, Division of Epidemiology, Prevention and Screening, Alberta Cancer Board, Edmonton, Alberta

Marilou Hervas, Division of Epidemiology, Prevention and Screening, Alberta Cancer Board; and EPICORE Center, University of Alberta, Edmonton, Alberta

Correspondence: Dr. Juanita Hatcher, Division of Epidemiology, Prevention and Screening, Alberta Cancer Board, 11560 University Avenue, Edmonton, Alberta T6G 1Z2; Fax: (780) 432-8645; E-mail: juanitah@cancerboard.ab.ca

[Previous][Table of Contents] [Next]

Last Updated: 2002-10-02 Top